Revvity agreed to sell its China Immunodiagnostics and ACD/Labs software business units, contributing to Q2 revenue growth.
2 reports, 2 independent
Updated Tue 00:00
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Revvity agreed to sell its China Immunodiagnostics and ACD/Labs software business units, contributing to Q2 revenue growth.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Revvity
American biotech company
Nothing else this week.